{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:49:42Z","timestamp":1782197382526,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02335-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:08:43Z","timestamp":1779851323000},"page":"1103-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer\u2019s Disease: A Systematic Review, Meta-Analysis and Meta-Regression"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4789-6019","authenticated-orcid":false,"given":"Anderson Matheus Pereira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Caruso Novaes","family":"Tudella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocilio Ribeiro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Virgilio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia Oliveira Machado","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria da Vit\u00f3ria Santos","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Vieira","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Haddad","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Henrique","family":"de Gobbi Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Silveira","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryvelton","family":"de Souza Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bernadete","family":"de Sousa Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"2","key":"2335_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136\u201342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763.","journal-title":"JAMA Psychiat"},{"issue":"10","key":"2335_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-016-0727-9","volume":"18","author":"G Airagnes","year":"2016","unstructured":"Airagnes G, Pelissolo A, Lavallee M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18(10):89. https:\/\/doi.org\/10.1007\/s11920-016-0727-9.","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"2335_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1176\/appi.ajp.2019.19030315","volume":"177","author":"M Osler","year":"2020","unstructured":"Osler M, Jorgensen MB. Associations of benzodiazepines, Z-Drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. Am J Psychiatry. 2020;177(6):497\u2013505. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19030315.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2335_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40263-016-0404-x","volume":"31","author":"FA Bietry","year":"2017","unstructured":"Bietry FA, Pfeil AM, Reich O, Schwenkglenks M, Meier CR. Benzodiazepine use and risk of developing Alzheimer\u2019s disease: a case-control study based on Swiss claims data. CNS Drugs. 2017;31(3):245\u201351. https:\/\/doi.org\/10.1007\/s40263-016-0404-x.","journal-title":"CNS Drugs"},{"issue":"3","key":"2335_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/jnnp-2019-321896","volume":"91","author":"W Xu","year":"2020","unstructured":"Xu W, Tan CC, Zou JJ, Cao XP, Tan L. Sleep problems and risk of all-cause cognitive decline or dementia: an updated systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91(3):236\u201344. https:\/\/doi.org\/10.1136\/jnnp-2019-321896.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2335_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/s0033291704003897","volume":"35","author":"H Verdoux","year":"2005","unstructured":"Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35(3):307\u201315. https:\/\/doi.org\/10.1017\/s0033291704003897.","journal-title":"Psychol Med"},{"issue":"1","key":"2335_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00002093-199803000-00002","volume":"12","author":"J Fastbom","year":"1998","unstructured":"Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12(1):14\u20137. https:\/\/doi.org\/10.1097\/00002093-199803000-00002.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"2335_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0898264318795567","volume":"31","author":"SL Burke","year":"2019","unstructured":"Burke SL, Hu T, Spadola CE, Burgess A, Li T, Cadet T. Treatment of sleep disturbance may reduce the risk of future probable Alzheimer\u2019s disease. J Aging Health. 2019;31(2):322\u201342. https:\/\/doi.org\/10.1177\/0898264318795567.","journal-title":"J Aging Health"},{"issue":"10","key":"2335_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jech-2011-200314","volume":"66","author":"J Gallacher","year":"2012","unstructured":"Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66(10):869\u201373. https:\/\/doi.org\/10.1136\/jech-2011-200314.","journal-title":"J Epidemiol Community Health"},{"issue":"10","key":"2335_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","volume":"38","author":"P Imfeld","year":"2015","unstructured":"Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine use and risk of developing Alzheimer\u2019s disease or vascular dementia: a case-control analysis. Drug Saf. 2015;38(10):909\u201319. https:\/\/doi.org\/10.1007\/s40264-015-0319-3.","journal-title":"Drug Saf"},{"key":"2335_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti de Gage","year":"2014","unstructured":"Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. BMJ. 2014;349:g5205. https:\/\/doi.org\/10.1136\/bmj.g5205.","journal-title":"BMJ"},{"issue":"3","key":"2335_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.medcli.2020.02.006","volume":"156","author":"P Aldaz","year":"2021","unstructured":"Aldaz P, Garjon J, Beitia G, et al. Association between benzodiazepine use and development of dementia. Med Clin (Barc). 2021;156(3):107\u201311. https:\/\/doi.org\/10.1016\/j.medcli.2020.02.006.","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"2335_CR13","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1111\/jgs.15018","volume":"65","author":"HT Cheng","year":"2017","unstructured":"Cheng HT, Lin FJ, Erickson SR, Hong JL, Wu CH. The association between the use of zolpidem and the risk of Alzheimer\u2019s disease among older people. J Am Geriatr Soc. 2017;65(11):2488\u201395. https:\/\/doi.org\/10.1111\/jgs.15018.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2335_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00952-y","volume":"14","author":"C Cavailles","year":"2022","unstructured":"Cavailles C, Berr C, Helmer C, Gabelle A, Jaussent I, Dauvilliers Y. Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimers Res Ther. 2022;14(1):12. https:\/\/doi.org\/10.1186\/s13195-021-00952-y.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"2335_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, Tahkapaa S, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037\u201347. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.003.","journal-title":"Eur Psychiatry"},{"key":"2335_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i90","volume":"352","author":"SL Gray","year":"2016","unstructured":"Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352:i90. https:\/\/doi.org\/10.1136\/bmj.i90.","journal-title":"BMJ"},{"issue":"1","key":"2335_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13311-019-00801-9","volume":"17","author":"LY Tseng","year":"2020","unstructured":"Tseng LY, Huang ST, Peng LN, Chen LK, Hsiao FY. Benzodiazepines, z-hypnotics, and risk of dementia: special considerations of half-lives and concomitant Use. Neurotherapeutics. 2020;17(1):156\u201364. https:\/\/doi.org\/10.1007\/s13311-019-00801-9.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"2335_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/14740338.2015.1014796","volume":"14","author":"S Billioti de Gage","year":"2015","unstructured":"Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015;14(5):733\u201347. https:\/\/doi.org\/10.1517\/14740338.2015.1014796.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2335_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.14283\/jpad.2023.78","volume":"11","author":"JH Hou","year":"2024","unstructured":"Hou JH, Sun SL, Tan CC, Huang YM, Tan L, Xu W. Relationships of hypnotics with incident dementia and Alzheimer\u2019s disease: a longitudinal study and meta-analysis. J Prev Alzheimers Dis. 2024;11(1):117\u201329. https:\/\/doi.org\/10.14283\/jpad.2023.78.","journal-title":"J Prev Alzheimers Dis."},{"issue":"5","key":"2335_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127836","volume":"10","author":"G Zhong","year":"2015","unstructured":"Zhong G, Wang Y, Zhang Y, Zhao Y. Association between benzodiazepine use and dementia: a meta-analysis. PLoS ONE. 2015;10(5):e0127836. https:\/\/doi.org\/10.1371\/journal.pone.0127836.","journal-title":"PLoS ONE"},{"issue":"2","key":"2335_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jamda.2019.08.006","volume":"21","author":"Dyer AH, Murphy C, Lawlor B, Kennelly SP, Group NS","year":"2020","unstructured":"Dyer AH, Murphy C, Lawlor B, Kennelly SP, Group NS. Cognitive outcomes of long-term Benzodiazepine and Related Drug (BDZR) use in people living with mild to moderate Alzheimer\u2019s disease: results from NILVAD. J Am Med Dir Assoc. 2020;21(2):194\u2013200. https:\/\/doi.org\/10.1016\/j.jamda.2019.08.006.","journal-title":"J Am Med Dir Assoc"},{"issue":"19","key":"2335_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJM197411072911906","volume":"291","author":"DJ Greenblatt","year":"1974","unstructured":"Greenblatt DJ, Shader RI. Drug therapy. Benzodiazepines (first of two parts). N Engl J Med. 1974;291(19):1011\u20135. https:\/\/doi.org\/10.1056\/NEJM197411072911906.","journal-title":"N Engl J Med"},{"key":"2335_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neuropharm.2017.10.022","volume":"128","author":"ML Brady","year":"2018","unstructured":"Brady ML, Pilli J, Lorenz-Guertin JM, et al. Depolarizing, inhibitory GABA type A receptor activity regulates GABAergic synapse plasticity via ERK and BDNF signaling. Neuropharmacology. 2018;128:324\u201339. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.022.","journal-title":"Neuropharmacology"},{"issue":"2","key":"2335_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3233\/JAD-151006","volume":"54","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thome F, et al. Regular benzodiazepine and Z-substance use and risk of dementia: an analysis of German claims data. J Alzheimers Dis. 2016;54(2):801\u20138. https:\/\/doi.org\/10.3233\/JAD-151006.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"2335_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.genhosppsych.2006.05.008","volume":"28","author":"GE Simon","year":"2006","unstructured":"Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374\u20138. https:\/\/doi.org\/10.1016\/j.genhosppsych.2006.05.008.","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"2335_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","volume":"14","author":"D O'Mahony","year":"2023","unstructured":"O\u2019Mahony D, Cherubini A, Guiteras AR, et al. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625\u201332. https:\/\/doi.org\/10.1007\/s41999-023-00777-y.","journal-title":"Eur Geriatr Med"},{"issue":"1","key":"2335_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-04742-7","volume":"24","author":"A Lukacisinova","year":"2024","unstructured":"Lukacisinova A, Reissigova J, Ortner-Hadziabdic M, et al. Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. BMC Geriatr. 2024;24(1):240. https:\/\/doi.org\/10.1186\/s12877-024-04742-7.","journal-title":"BMC Geriatr"},{"issue":"7","key":"2335_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","volume":"71","author":"A Renom-Guiteras","year":"2015","unstructured":"Renom-Guiteras A, Meyer G, Thurmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861\u201375. https:\/\/doi.org\/10.1007\/s00228-015-1860-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"2335_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.3825","volume":"25","author":"C Huerta","year":"2016","unstructured":"Huerta C, Abbing-Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):56\u201365. https:\/\/doi.org\/10.1002\/pds.3825.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2335_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/JGP.0b013e3181e049ca","volume":"19","author":"CS Wu","year":"2011","unstructured":"Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19(2):151\u20139. https:\/\/doi.org\/10.1097\/JGP.0b013e3181e049ca.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"2335_CR31","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/alz.12362","volume":"17","author":"KB Rajan","year":"2021","unstructured":"Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021;17(12):1966\u201375. https:\/\/doi.org\/10.1002\/alz.12362.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2335_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/JGP.0b013e3181a65210","volume":"17","author":"CS Wu","year":"2009","unstructured":"Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry. 2009;17(7):614\u201320. https:\/\/doi.org\/10.1097\/JGP.0b013e3181a65210.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"2335_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jalz.2015.10.006","volume":"12","author":"D Shash","year":"2016","unstructured":"Shash D, Kurth T, Bertrand M, et al. Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study. Alzheimers Dement. 2016;12(5):604\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2015.10.006.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2335_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/psyg.12239","volume":"17","author":"TT Chan","year":"2017","unstructured":"Chan TT, Leung WC, Li V, et al. Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study. Psychogeriatrics. 2017;17(5):310\u20136. https:\/\/doi.org\/10.1111\/psyg.12239.","journal-title":"Psychogeriatrics"},{"issue":"8","key":"2335_CR35","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/alz.12117","volume":"16","author":"W Xu","year":"2020","unstructured":"Xu W, Tan L, Su BJ, et al. Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease pathology in cognitively intact older adults: the CABLE study. Alzheimers Dement. 2020;16(8):1146\u201352. https:\/\/doi.org\/10.1002\/alz.12117.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2335_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40263-018-0535-3","volume":"32","author":"R Penninkilampi","year":"2018","unstructured":"Penninkilampi R, Eslick GD. A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs. 2018;32(6):485\u201397. https:\/\/doi.org\/10.1007\/s40263-018-0535-3.","journal-title":"CNS Drugs"},{"issue":"7","key":"2335_CR37","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.1007\/s12035-025-04821-9","volume":"62","author":"K Vakili","year":"2025","unstructured":"Vakili K, Fathi M, Ebrahimi R, et al. Use of drugs affecting GABA(A) receptors and the risk of developing Alzheimer\u2019s disease and dementia: a meta-analysis and literature review. Mol Neurobiol. 2025;62(7):9449\u201368. https:\/\/doi.org\/10.1007\/s12035-025-04821-9.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2335_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3988\/jcn.2019.15.1.9","volume":"15","author":"Q He","year":"2019","unstructured":"He Q, Chen X, Wu T, Li L, Fei X. Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies. J Clin Neurol. 2019;15(1):9\u201319. https:\/\/doi.org\/10.3988\/jcn.2019.15.1.9.","journal-title":"J Clin Neurol"},{"issue":"10","key":"2335_CR39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/phar.2170","volume":"38","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, da Mata BPM, Mastroianni PC. Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis. Pharmacotherapy. 2018;38(10):1010\u201320. https:\/\/doi.org\/10.1002\/phar.2170.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2335_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s41999-021-00553-w","volume":"13","author":"P Ferreira","year":"2022","unstructured":"Ferreira P, Ferreira AR, Barreto B, Fernandes L. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews. Eur Geriatr Med. 2022;13(1):19\u201332. https:\/\/doi.org\/10.1007\/s41999-021-00553-w.","journal-title":"Eur Geriatr Med"},{"key":"2335_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"2335_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPTTJ Higgins","year":"2019","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 1st ed. Wiley; 2019.","edition":"1st ed."},{"key":"2335_CR43","doi-asserted-by":"publisher","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. https:\/\/doi.org\/10.1001\/jama.283.15.2008","DOI":"10.1001\/jama.283.15.2008"},{"issue":"19","key":"2335_CR44","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4045\/tidsskr.08.0403","volume":"129","author":"A Fetveit","year":"2009","unstructured":"Fetveit A, Bjorvatn B. Sleep disorders in the elderly. Tidsskr Nor Laegeforen. 2009;129(19):2004\u20136. https:\/\/doi.org\/10.4045\/tidsskr.08.0403. (Sovnforstyrrelser hos eldre.).","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"2","key":"2335_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20050","volume":"12","author":"DA Regier","year":"2013","unstructured":"Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. World Psychiatry. 2013;12(2):92\u20138. https:\/\/doi.org\/10.1002\/wps.20050.","journal-title":"World Psychiatry"},{"issue":"3","key":"2335_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2335_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2335_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"issue":"3","key":"2335_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"7109","key":"2335_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"11","key":"2335_CR51","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559\u201373. https:\/\/doi.org\/10.1002\/sim.1187.","journal-title":"Stat Med"},{"issue":"1","key":"2335_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jrsm.5","volume":"1","author":"LV Hedges","year":"2010","unstructured":"Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Methods. 2010;1(1):39\u201365. https:\/\/doi.org\/10.1002\/jrsm.5.","journal-title":"Res Synth Methods"},{"issue":"4","key":"2335_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Mental Health"},{"issue":"7650","key":"2335_CR54","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"4","key":"2335_CR55","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-201319","volume":"81","author":"W Jeong","year":"2021","unstructured":"Jeong W, Joo JH, Kim H, Kim YK, Park EC, Jang SI. Association between the use of hypnotics and the risk of Alzheimer\u2019s Disease. J Alzheimers Dis. 2021;81(4):1381\u20139. https:\/\/doi.org\/10.3233\/JAD-201319.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2335_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/acps.12909","volume":"138","author":"V Tapiainen","year":"2018","unstructured":"Tapiainen V, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM. The risk of Alzheimer\u2019s disease associated with benzodiazepines and related drugs: a nested case-control study. Acta Psychiatr Scand. 2018;138(2):91\u2013100. https:\/\/doi.org\/10.1111\/acps.12909.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2335_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/acps.13380","volume":"145","author":"M Tournier","year":"2022","unstructured":"Tournier M, Pambrun E, Maumus-Robert S, Pariente A, Verdoux H. The risk of dementia in patients using psychotropic drugs: antidepressants, mood stabilizers or antipsychotics. Acta Psychiatr Scand. 2022;145(1):56\u201366. https:\/\/doi.org\/10.1111\/acps.13380.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2335_CR58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1060028019882037","volume":"54","author":"M Nafti","year":"2020","unstructured":"Nafti M, Sirois C, Kroger E, Carmichael PH, Laurin D. Is benzodiazepine use associated with the risk of dementia and cognitive impairment-not dementia in older persons? The Canadian Study of Health and Aging. Ann Pharmacother. 2020;54(3):219\u201325. https:\/\/doi.org\/10.1177\/1060028019882037.","journal-title":"Ann Pharmacother"},{"issue":"3-4","key":"2335_CR59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000454881","volume":"47","author":"MM Islam","year":"2016","unstructured":"Islam MM, Iqbal U, Walther B, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47(3\u20134):181\u201391. https:\/\/doi.org\/10.1159\/000454881.","journal-title":"Neuroepidemiology"},{"issue":"11","key":"2335_CR60","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/npp.2013.137","volume":"38","author":"PL Soto","year":"2013","unstructured":"Soto PL, Ator NA, Rallapalli SK, et al. Allosteric modulation of GABA(A) receptor subtypes: effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected]. Neuropsychopharmacology. 2013;38(11):2315\u201325. https:\/\/doi.org\/10.1038\/npp.2013.137.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"2335_CR61","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1073\/pnas.0307231101","volume":"101","author":"VB Caraiscos","year":"2004","unstructured":"Caraiscos VB, Elliott EM, You-Ten KE, et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A. 2004;101(10):3662\u20137. https:\/\/doi.org\/10.1073\/pnas.0307231101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2335_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112068","volume":"9","author":"T Berdyyeva","year":"2014","unstructured":"Berdyyeva T, Otte S, Aluisio L, et al. Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope. PLoS ONE. 2014;9(11):e112068. https:\/\/doi.org\/10.1371\/journal.pone.0112068.","journal-title":"PLoS ONE"},{"issue":"1","key":"2335_CR63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1124\/mol.106.029595","volume":"71","author":"F Sancar","year":"2007","unstructured":"Sancar F, Ericksen SS, Kucken AM, Teissere JA, Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Mol Pharmacol. 2007;71(1):38\u201346. https:\/\/doi.org\/10.1124\/mol.106.029595.","journal-title":"Mol Pharmacol"},{"issue":"7","key":"2335_CR64","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert P","year":"2023","unstructured":"American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052\u201381. https:\/\/doi.org\/10.1111\/jgs.18372.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2335_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s43141-021-00224-0","volume":"19","author":"A Ghit","year":"2021","unstructured":"Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19(1):123. https:\/\/doi.org\/10.1186\/s43141-021-00224-0.","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"2335_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/jdad3010002","volume":"3","author":"AR Butler","year":"2026","unstructured":"Butler AR, Kim N, Hunsberger HC. Unresolved controversies: the effect of benzodiazepines on cognition and Alzheimer\u2019s disease. J Dementia Alzheimer\u2019s Dis. 2026;3(1):2. https:\/\/doi.org\/10.3390\/jdad3010002.","journal-title":"J Dementia Alzheimer's Dis"},{"issue":"24","key":"2335_CR67","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197\u2013204. https:\/\/doi.org\/10.1212\/01.wnl.0000271090.28148.24.","journal-title":"Neurology"},{"issue":"6","key":"2335_CR68","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755\u201366. https:\/\/doi.org\/10.1007\/s00401-014-1349-0.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2335_CR69","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099. (Erratum in: Brain. 2019 Jul 1;142(7):e37. doi: 10.1093\/brain\/awz163.).","journal-title":"Brain"},{"issue":"2","key":"2335_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jalz.2017.10.009","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer\u2019s disease in the United States. Alzheimers Dement. 2018;14(2):121\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2017.10.009.","journal-title":"Alzheimers Dement"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02335-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:11Z","timestamp":1782196751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02335-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02335-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AMPS, GCNT, ORG, FVR, MAOMP, MVSN, and BVN drafted the initial version of the manuscript. AMPS, MBSM, FHGP, and PFHC conceived the study, designed the methodology, and ensured validation. AMPS and ESF performed data extraction and statistical analyses. MBSM, MVSN, BVN, and FHGP conducted the risk of bias and quality assessments. FSD, GP, DHS, PFHC, and FHGP critically revised the manuscript and supervised the overall project. All authors contributed to the interpretation of the results and approved the final version of the manuscript. AMPS assumes full responsibility for the integrity of the work as a whole, including study design, data access, and the decision to submit for publication. All authors had full access to the data and accepted responsibility for the submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}